Table 2.

Describes the types of mCHT and use as monotherapy (single agent), or as combination with other drugs

	Type of mCHT in TNBC (n = 97) N (%)	Type of mCHT in Luminal (n = 487) N (%)
VRL-based	44 (45.4)	261 (53.6)
VRL single agent	32 (72.7)	170 (65.1)
VRL + CAPE/CTX	12 (27.3)	91 (34.9)
CAPE-based	22 (22.7)	121 (24.8)
CAPE single agent	21 (95.5)	111 (91.7)
CAPE + CTX	1 (4.5)	8 (6.6)
CAPE + Other drugs	–	2 (1.7)
CTX-based	30 (30.9)	96 (19.7)
CTX single agent	30 (100)	87 (90.6)
CTX + Other drugs	–	9 (9.4)
MTX-based	1 (1.0)	9 (1.8)